Highly prevalent alterations in human prostate cancer, such as gains of the MYC oncogene and deletions of the tumor suppressors NKX3-1, PTEN, RB1, and CDKN1B, were either absent or present in only very limited cases40. This evidence concerns the gene PTEN and prostate carcinoma.